Chemoembolization for liver metastases from medullary thyroid carcinoma

Details

Serval ID
serval:BIB_963F663C4CDC
Type
Article: article from journal or magazin.
Collection
Publications
Title
Chemoembolization for liver metastases from medullary thyroid carcinoma
Journal
J Clin Endocrinol Metab
Author(s)
Fromigue J., De Baere T., Baudin E., Dromain C., Leboulleux S., Schlumberger M.
ISSN-L
0021-972X (Print)0021-972X (Linking)
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
91
Number
7
Pages
2496-9
Language
english
Notes
Fromigue, JDe Baere, TBaudin, EDromain, CLeboulleux, SSchlumberger, MengCase ReportsReview2006/04/13 09:00J Clin Endocrinol Metab. 2006 Jul;91(7):2496-9. Epub 2006 Apr 11.
Abstract
BACKGROUND: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor. Distant metastases are the main cause of cancer-related death. Systemic chemotherapy produces only rare tumor responses. Somatostatin analogs and other available modalities are poorly effective to control symptoms. AIMS: The aim of our study was to evaluate the impact of liver transarterial chemoembolization (TACE) in MTC patients with predominant and progressive liver metastases. PATIENTS AND METHODS: Twelve MTC patients underwent 18 TACE courses (mean, 1.5; range, 1-2). Response evaluation criteria in solid tumors were used to evaluate tumor responses. Symptomatic responses were defined by more than a 25% decrease of symptoms intensity. RESULTS: Partial radiological tumor response was obtained in five patients (42%) with a median duration of 17 months (mean, 19; range, 15-28 months), stabilization in five (42%) with a median duration of 24 months (mean, 24; range, 4-39 months), and progression in the remaining two (16%). The five partial tumor responses were observed in the nine patients with less than 30% liver involvement. Clinical response was observed in two of the five patients with diarrhea. Carcinoembryonic antigen did not appear to be a useful marker in this setting. Significant grade 3-4 toxicity was observed in one patient who had a major tumor necrosis after TACE. CONCLUSION: TACE should be considered for treating MTC patients with progressive and predominant liver metastasis, and preferably at an early stage during the course of metastatic disease.
Keywords
Adult, Aged, Aged, 80 and over, Calcitonin/blood, Carcinoembryonic Antigen/blood, Carcinoma, Medullary/*secondary, *Chemoembolization, Therapeutic/adverse effects/methods, Female, Humans, Liver/blood supply, Liver Neoplasms/radiography/*secondary/*therapy, Male, Middle Aged, *Thyroid Neoplasms, Tomography, X-Ray Computed, Treatment Outcome
Open Access
Yes
Create date
16/09/2016 10:14
Last modification date
20/08/2019 14:58
Usage data